The EGRIFTA SV and EGRIFTA WR labels on where tesamorelin is injected, the volume each formulation draws, the vial arithmetic, and the doses in units.
Of the injected compounds on this site, tesamorelin has the narrowest site instruction. The semaglutide and tirzepatide labels list three places and say exposure is similar at all of them; the tesamorelin labels list one — the abdomen — and say nothing about anywhere else. What makes the search worth a page is the rest of the label: two current formulations with different diluents, volumes and doses that are explicitly not interchangeable, and a seven-day vial whose arithmetic does not quite close. This page reports the EGRIFTA SV and EGRIFTA WR labels (read 2026-10-03) and converts the doses to syringe units. It describes; it gives no instruction.
General subcutaneous technique is on the peptide injection guide; the three-site labels for comparison are where to inject tirzepatide and where to inject semaglutide. The dosage record — the 2 mg pivotal regimen, the registry and the vendor figures — is on the tesamorelin dosage page.
The site, as both labels state it
| Label element |
EGRIFTA SV (2 mg vial) |
EGRIFTA WR (11.6 mg vial) |
| Site |
Abdomen |
Abdomen |
| Rotation |
Different areas of the abdomen |
Different areas of the abdomen |
| Avoided |
Scar tissue, bruises, navel |
Scar tissue, bruises, navel |
| Distance from navel (Instructions for Use) |
At least 2 inches (5 cm) |
At least 2 inches (5 cm) |
| Other sites |
None named |
None named |
The single site is not a statement that other sites fail; it is the absence of data. Tesamorelin was developed and approved for one indication — reducing excess abdominal fat in adults with HIV-associated lipodystrophy — and its labels describe abdominal injection only. Where the GLP-1 labels print a pharmacokinetic finding ("similar exposure" at three sites), the tesamorelin labels print only the instruction. A page that says tesamorelin "works the same in the thigh" is reporting something no label or trial in the record states.
|
EGRIFTA SV |
EGRIFTA WR |
| Vial |
2 mg, single dose |
11.6 mg, single-patient use |
|---|
| Diluent (supplied) |
0.5 mL Sterile Water for Injection |
1.3 mL Bacteriostatic Water for Injection, USP |
|---|
| Concentration after mixing |
4 mg/mL (2 mg per 0.5 mL) |
8 mg/mL (as labelled) |
|---|
| Daily dose |
1.4 mg |
1.28 mg |
|---|
| Volume drawn |
0.35 mL = 35 units |
0.16 mL = 16 units |
|---|
| After the dose |
Remainder discarded immediately |
Vial kept at room temperature, used for 7 days |
|---|
| Half-life (healthy subjects) |
8 minutes |
11 minutes |
|---|
The labels state that the systemic exposure of 1.4 mg SV, 1.28 mg WR and the original 2 mg dose is similar, and that SV and WR "are not substitutable". The milligram figures differ because the formulations differ; the exposure is what was matched. That is the same logic as the semaglutide tablets that are matched on exposure and not on milligrams (see oral semaglutide dosage).
The WR vial is the only multi-day tesamorelin presentation, and the only one supplied with a preserved diluent. Its arithmetic is worth doing once. At the label's 8 mg/mL, 11.6 mg makes about 1.45 mL of solution — about 0.15 mL more than the 1.3 mL of diluent added, because dissolved powder takes up volume (set out on tesamorelin reconstitution). Seven daily doses of 0.16 mL use 1.12 mL, or 8.96 mg, leaving about 0.33 mL (2.6 mg) in the vial when it is discarded on day 7. Dividing 11.6 by 1.3 gives 8.9 mg/mL, which is not the label's figure: a volume worked out from it would deliver about 10% less than intended (1.15 mg instead of 1.28 mg).
Injection site reactions
Both labels carry the same warning: injection site reactions — erythema, pruritus, pain, irritation and bruising — in 25% of tesamorelin-treated patients against 14% on placebo during the first 26 weeks of the clinical trials. The labels' stated measure is rotation within the abdomen. They also list hypersensitivity reactions (itching, redness, flushing, hives, rash) separately; those are systemic, not local.
How fast it acts
Tesamorelin is in and out within the hour. The labels give a median time to peak concentration of 0.15 hours — about 9 minutes — and a mean elimination half-life of 8 minutes for SV and 11 minutes for WR. Absolute bioavailability of the original 1 mg/vial product after subcutaneous injection was under 4%. Nothing accumulates from day to day, which is why the dose is daily and why timing questions matter less than they do for weekly molecules. Neither label sets a time of day.
The label doses in units, research vials
Research vials of tesamorelin are sold as 5 mg and 10 mg powders, which no label covers. Units on a U-100 syringe = mg ÷ mg/mL × 100.
| Dose |
2.5 mg/mL |
4 mg/mL (SV mix) |
5 mg/mL |
8 mg/mL (WR mix) |
10 mg/mL |
| 1.28 mg (WR label) |
51.2 units |
32 units |
25.6 units |
16 units |
12.8 units |
| 1.4 mg (SV label) |
56 units |
35 units |
28 units |
17.5 units |
14 units |
| 2 mg (original label, pivotal trial) |
80 units |
50 units |
40 units |
25 units |
20 units |
A 5 mg vial with 1 mL, or a 10 mg vial with 2 mL, gives 5 mg/mL; a 10 mg vial with 1 mL gives 10 mg/mL. Water volumes per vial size are on tesamorelin reconstitution, the conversion on mg to units, and any vial in the calculator's tesamorelin setting. Sermorelin, the GHRH analogue whose label was withdrawn, has no current site instruction at all; what its trial and the compounders state is on where sermorelin is injected.
What is not established
No label covers a 5 mg or 10 mg research vial, an injection site other than the abdomen, or any use beyond HIV-associated abdominal fat. The site and exposure statements above come from the approved products. Storage and the general mixing procedure are covered on Medibact's how to store peptides and how to reconstitute peptides pages, and the compound in Medibact's Tesamorelin guide. Nothing on this page is an instruction; technique and dose belong with the prescriber. No trial cycled it; the durations on record and the result after stopping are on the tesamorelin course-length page.
Sources and dates
Opened 2026-10-03: the EGRIFTA SV label (set id 3d783378-b02d-4f19-99dd-0fc91a042224) and the EGRIFTA WR label (set id 839334d3-8c1d-4c26-9036-2ab524a6ea75) via openFDA, both BLA 022505, Theratechnologies, effective 2026-07-29 — sections 2.1–2.2, 3, 5.5–5.6, 12.3 and the Instructions for Use (revised 03/2024 and 03/2025). Units, volumes and the WR vial balance are arithmetic by this site. Corrections go to the contact page.
